|
|
 |
|
Viewing report
|
|
|
|
Pipeline Insight: Hematological Malignancies - Pursuit For The Next Blockbuster Intensifies
Datamonitor, March 2007, Pages: 374
Unmet needs across the hematological malignancies remain high, with most traditional therapies conferring low levels of specificity and high toxicity.
Pipeline candidates classified as molecular targeted therapies, cytotoxic therapies and immunotherapeutic agents, may offer attractive therapeutic additions and our insight into their clinical and commercial potential is provided.
Scope of this title:
Research and analysis of the hematological malignancies pipeline with in-depth clinical and commercial assessment of Phase III candidates
Seven major pharmaceutical market sales forecasts to 2016 for key pipeline candidates incorporating product specific assumptions and events
Segmentation and examination of product pipeline by developmental phase, class, indication and developer
Insight and analysis of the hematological malignancies market potential including commercial opportunity and disease epidemiology
Highlights of this title:
180 different pipeline candidates have been identified of which 22 are in late-phase development. These existing candidates have a forecast sales potential of up to $3.61 billion in the seven major pharmaceutical markets by 2016. Agents holding strong commercial potential include Novartis Gleevec-follow-on, Tasigna (nilotinib), and Genzymes already approved purine analog Clolar (clofarabine) which is in development for acute myeloid leukemia. Other notable candidates include the anti-idiotype therapeutic vaccines and Biogen Idecs anti-CD23 MAb, lumiliximab. Over 50% of the products are being investigated in acute and/or chronic leukemia. However, as an individual hematological subtype, NHL attracts the greatest attention from developers with 53 (29%) products in the pipeline despite the malignancy being comparatively well served by existing treatment regimens.
Reasons to order your copy:
Acquire a detailed appreciation and impartial perspective of the entire hematological malignancies developmental pipeline
Identify the key products in late-phase development based on sales forecasts to 2016 and ours drug assessment methodology
Consider, assess and react to opportunities and risks influencing the future potential of products in the hematological malignancies pipeline
Customers who bought this item also bought
Hematological Malignancies: Companies Target Niche Indications to Facilitate Market Entry
Pipeline Insight: Hematological Malignancies - Targeted Treatments And Immunotherapy Infuse New Blood
Global Pipeline Review & Analysis of Hematological Malignancies
Analytical Tool - Hematological Cancers
Prospects for the Phase III Bapineuzumab Trial
Pipeline Insight: Molecular Targeted Cancer Therapies - More Pipeline Activity, Less Product Differentiation
Hematological Cancers - A Therapeutic & Competitive Insight
TNFerade Phase III Clinical Trial Results Call - GenVec, Inc., - Earnings Transcript
Trial TRAX - Multiple Sclerosis - Clinical Trial Monitoring Brief
Inhalers Clinical Trial Analysis
Antibody drug conjugates for cancer treatment: Clinical Trial Pipeline
Pharmacogenomics for Clinical Use and in Drug Development
|
|
|
|
